Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Female Contraception Pipeline Drugs Market Report Overview
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and natural methods.
The Female Contraception pipeline drugs market research report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.
Female Contraception Pipeline Drugs Market Segmentation by Targets
The key targets in the Female Contraception pipeline drugs market are Progesterone Receptor, Estrogen Receptor, Anti Muellerian Hormone Type 2 Receptor, Cation Channel Sperm Associated Protein 1, and others. Progesterone Receptor has the highest number of products in development in the Female Contraception pipeline drugs market in 2022.
Female Contraception Pipeline Drugs Market Analysis by Targets
For more target insights into the Female Contraception pipeline drugs market, download a free report sample
Female Contraception Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Female Contraception pipeline drugs market are Progesterone Receptor Agonist, Estrogen Receptor Agonist, Progesterone Receptor Antagonist, Anti Muellerian Hormone Type 2 Receptor Agonist, and others. Progesterone Receptor Agonist leads the Female Contraception pipeline drugs market in terms of MoA.
Female Contraception Pipeline Drugs Market Analysis by Mechanisms of Action
For more MoA insights into the Female Contraception pipeline drugs market, download a free report sample
Female Contraception Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Female Contraception pipeline drugs market are oral, vaginal, transdermal, subcutaneous, topical, parenteral, and buccal. The oral RoA has the highest number of Female Contraception drugs in development in 2022.
Female Contraception Pipeline Drugs Market Analysis by Routes of Administration
For more RoA insights into the Female Contraception pipeline drugs market, download a free report sample
Female Contraception Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Female Contraception pipeline drugs market are small molecule, monoclonal antibody, polymer, recombinant protein, and toxoid vaccine. Small molecule leads the Female Contraception pipeline drugs market in terms of molecule type.
Female Contraception Pipeline Drugs Market Analysis by Molecule Types
For more molecule type insights into the Female Contraception drugs market, download a free report sample
Female Contraception Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Female Contraception pipeline drugs market are Evestra Inc, Agile Therapeutics Inc, Viramal Ltd, and Adare Pharma Solutions. Evestra Inc accounted for the highest number of Female Contraception pipeline drugs in 2022.
Female Contraception Pipeline Drugs Market Analysis by Companies
To know more about the leading Female Contraception pipeline drugs market players, download a free report sample
Female Contraception Pipeline Products Market Overview
Key Targets | Progesterone Receptor, Estrogen Receptor, Anti Muellerian Hormone Type 2 Receptor, Cation Channel Sperm Associated Protein 1, and Others |
Key Mechanisms of Action | Progesterone Receptor Agonist, Estrogen Receptor Agonist, Progesterone Receptor Antagonist, Anti Muellerian Hormone Type 2 Receptor Agonist, and Others |
Key Routes of Administration | Oral, Vaginal, Transdermal, Subcutaneous, Topical, Parenteral, and Buccal |
Key Molecule Type | Small Molecule, Monoclonal Antibody, Polymer, Recombinant Protein, and Toxoid Vaccine |
Leading Companies | Evestra Inc, Agile Therapeutics Inc, Viramal Ltd, Adare Pharma Solutions, and Others. |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception.
- The pipeline guide reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Female Contraception
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Female Contraception pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Agile Therapeutics Inc
Dare Bioscience Inc
Evestra Inc
Evofem Biosciences Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Hyundai Pharma Co Ltd
InSilico Medicine
Insud Pharma
Lyndra Therapeutics Inc.
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Noven Pharmaceuticals Inc
Ohana BioSciences Inc
Organon & Co
Orion Biotechnology Canada Ltd
Schrodinger Inc
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Yaso Therapeutics Inc
YourChoice Therapeutics Inc
ZabBio Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Female Contraception pipeline drugs market?
The key targets in the Female Contraception pipeline drugs market are Progesterone Receptor, Estrogen Receptor, Anti Muellerian Hormone Type 2 Receptor, Cation Channel Sperm Associated Protein 1, and Others.
-
What are the key mechanisms of action in the Female Contraception pipeline drugs market?
The key MoA in the Female Contraception pipeline drugs market are Progesterone Receptor Agonist, Estrogen Receptor Agonist, Progesterone Receptor Antagonist, Anti Muellerian Hormone Type 2 Receptor Agonist, and Others.
-
What are the key routes of administration in the Female Contraception pipeline drugs market?
The key RoA in the Female Contraception pipeline drugs market are oral, vaginal, transdermal, subcutaneous, topical, parenteral, and buccal.
-
What are the key molecule types in the Female Contraception pipeline drugs market?
The key molecule types in the Female Contraception pipeline drugs market are small molecule, monoclonal antibody, polymer, recombinant protein, and toxoid vaccine.
-
Which are the leading companies in the Female Contraception pipeline drugs market?
Some of the leading companies in the Female Contraception pipeline drugs market are Evestra Inc, Agile Therapeutics Inc, Viramal Ltd, and Adare Pharma Solutions.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.